Chimeric antigen receptor T cell (CAR T) therapy has produced remarkable clinical responses in B cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as Acute Myeloid Leukemia (AML), that may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One …